Format
Sort by

Send to

Choose Destination

Search results

Items: 13

1.

Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique.

Lamorde M, Fillekes Q, Sigaloff K, Kityo C, Buzibye A, Kayiwa J, Merry C, Nakatudde-Katumba L, Burger D, de Wit TF.

BMC Infect Dis. 2014 Sep 1;14:473. doi: 10.1186/1471-2334-14-473.

2.

The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.

Musiime V, Fillekes Q, Kekitiinwa A, Kendall L, Keishanyu R, Namuddu R, Young N, Opilo W, Lallemant M, Walker AS, Burger D, Gibb DM.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):148-54. doi: 10.1097/QAI.0000000000000135.

PMID:
24828266
3.

Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.

Fillekes Q, Kendall L, Kitaka S, Mugyenyi P, Musoke P, Ndigendawani M, Bwakura-Dangarembizi M, Gibb DM, Burger D, Walker AS; ARROW Trial Team.

Pediatr Infect Dis J. 2014 May;33(5):495-8. doi: 10.1097/INF.0000000000000143.

4.

Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity.

Baranyai D, Muro E, Gödtel-Armbrust U, Schirmer MA, Kisanga E, Diczfalusy U, Fillekes Q, Schuurman R, Burger D, Wojnowski L.

J Antimicrob Chemother. 2014 Jul;69(7):1933-7. doi: 10.1093/jac/dku086. Epub 2014 Apr 2.

5.

Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.

Fillekes Q, Muro EP, Chunda C, Aitken S, Kisanga ER, Kankasa C, Thomason MJ, Gibb DM, Walker AS, Burger DM.

J Antimicrob Chemother. 2013 Nov;68(11):2609-15. doi: 10.1093/jac/dkt246. Epub 2013 Jul 17.

6.

Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?

Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, Chintu C, Gibb DM, Walker AS, Burger DM; CHAPAS-1 trial team.

AIDS. 2013 Aug 24;27(13):2111-5. doi: 10.1097/QAD.0b013e3283620811.

PMID:
23595153
7.

Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study.

Zoufaly A, Fillekes Q, Hammerl R, Nassimi N, Jochum J, Drexler JF, Awasom CN, Sunjoh F, Burchard GD, Burger DM, van Lunzen J, Feldt T.

Antivir Ther. 2013;18(5):681-90. doi: 10.3851/IMP2562. Epub 2013 Mar 18.

PMID:
23502762
8.

Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.

Semvua HH, Mtabho CM, Fillekes Q, van den Boogaard J, Kisonga RM, Mleoh L, Ndaro A, Kisanga ER, van der Ven A, Aarnoutse RE, Kibiki GS, Boeree MJ, Burger DM.

Antivir Ther. 2013;18(1):105-13. doi: 10.3851/IMP2413. Epub 2012 Oct 5.

PMID:
23043067
9.

Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.

Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, Ferrier A, Chintu C, Walker AS, Gibb DM, Burger DM.

AIDS. 2012 Sep 10;26(14):1795-800. doi: 10.1097/QAD.0b013e32835705fd.

PMID:
22739394
10.

Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms.

Mutwa PR, Fillekes Q, Malgaz M, Tuyishimire D, Kraats Rv, Boer KR, Burger DM, van Schaik RH, Muganga N, Geelen SP.

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):400-4. doi: 10.1097/QAI.0b013e3182569f57.

PMID:
22481606
11.

Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes.

Aitken SC, Kliphuis A, Wallis CL, Chu ML, Fillekes Q, Barth R, Stevens W, Rinke de Wit TF, Schuurman R.

J Clin Virol. 2012 May;54(1):21-5. doi: 10.1016/j.jcv.2012.01.010. Epub 2012 Feb 3.

PMID:
22306272
12.

Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention.

Muro EP, Fillekes Q, Kisanga ER, L'homme R, Aitken SC, Mariki G, Van der Ven AJ, Dolmans W, Schuurman R, Walker AS, Gibb DM, Burger DM.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):266-73. doi: 10.1097/QAI.0b013e31824234d8.

PMID:
22134145
13.

Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.

Fillekes Q, Natukunda E, Balungi J, Kendall L, Bwakura-Dangarembizi M, Keishanyu R, Ferrier A, Lutakome J, Gibb DM, Burger DM, Walker AS; ARROW Trial Team.

J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):392-8. doi: 10.1097/QAI.0b013e318235e560.

PMID:
21926634
Items per page

Supplemental Content

Loading ...
Write to the Help Desk